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Conclusions: To directly investigate the functional role of AMF on anti-
apoptosis, we transfected AMF plasmid into NHAC-kn. These cells did
not express caspase-9 and Apaf-1, and were resistant to shear stress
induced apoptosis. Treatment with MAPK or PI3K inhibitors suppressed
these anti-apoptotic characters. Our results strongly suggest that AMF
regulates expression of caspase-9 and Apaf-1 via complex pathway
mainly through the activation of MAPK and PI3K signaling pathway.
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Purpose: While the adult human cartilage is an avascular tissue, the
joint deterioration that occurs during osteoarthritis can lead to cartilage
neovascularization. In this situation, the expression of angiogenic factors
plays a key role controlling not only angiogenesis but also chondrocyte
metabolism. Thus, our aim was to study the effects of different drugs
that are commonly used in the treatment of osteoarthritis on the gene
expression and protein synthesis of neoangiogenic mediators in human
osteoarthritic chondrocytes (HOC) stimulated with Il-1b.
Methods: Chondrocytes were obtained from the joint specimens of
OA patients who underwent total knee replacement surgery. We used
quiescent cells stimulated with 1U/ml Il-1b, and studied the effects of glu-
cosamine sulfate (GS, 5×10−5 M), chondrointin sulfate (CS, 2×10−3 M),
celecoxib (CBX, 10−6 M), diclofenac (DCF, 10−6 M), meloxicam (MXC,
10−6 M) and indomethacin (IND, 10−6 M) in the gene expression and
protein synthesis of vascular endothelial growth factor (VEGF), two of
its receptors (VEGFR1 and VEGFR2) and a transcription factor that
regulates neoangiogenesis development, HIF-1a. All drugs were tested
at the mean peak plasma concentration (Cmax) obtained after oral
administration of a therapeutic dose. To study the gene expression we
carried out real-time PCR studies, and Western blot analysis was used
to study protein synthesis.
Results: Il-1b induced in HOC a time and dose-dependent increase in the
gene expression of HIF-1a, VEGF and VEGFR2, peaking at 24 hours of
incubation for VEGF and at 4 hours of incubation for HIF-1a and VEGFR2.
In whole cell extracts we showed that HIF-1a induction evoked by Il-1b
was not modiﬁed by any of the drugs tested. Regarding VEGF protein
synthesis, Il-1b was able to signiﬁcantly increase the synthesis of the
spliced isoform VEGF165, and this increase was signiﬁcantly inhibited
by the presence of GS or CS in the culture media (Il-1b: 2.5-fold; GS:
1.5-fold*; CS: 1.3-fold*; *p< 0.05 vs. Il-1b). However, none of the different
NSAID tested was able to modify VEGF165 synthesis by stimulated HOC.
Intriguing, VEGF mRNA expression did not correlate with protein synthe-
sis in stimulated chondrocytes, because all the drugs tested signiﬁcantly
inhibited the induction in VEGF mRNA expression evoked by Il-1b. As
VEGF has been found to act as an autocrine factor on chondrocytes,
we preformed an analysis of VEGFR1 and VEGFR2 regulation in HOC.
No signal could be detected for VEGFR1 by western blot studies. Il-1b
stimulation signiﬁcantly induced VEGFR2 gene expression, and it was
further induced in the presence of both SYSADOAs and NSAIDs. By
western blot studies, we showed that Il-1b increase the synthesis of both
immature VEGFR2 and glycosylated VEGFR2 in HOC, although none of
the drugs tested signiﬁcantly modiﬁed the synthesis of VEGFR2 induced
by Il-1b.
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Conclusions: Increased levels of VEGF165 protein synthesis are de-
tected in the cells stimulated with Il-1b. Both GS and CS inhibited the
increase in this protein induced by the stimulation, while NSAIDs were
unable to modify VEGF165 presence. Our data suggests that NSAIDs
and SYSADOAs could have a different proﬁle in controlling the presence
of angiogenic mediators in the OA cartilage.
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Purpose: Articular cartilage in human osteoarthritis (OA) has more
apoptotic chondrocytes than that of normal cartilage, and apoptosis
has been considered to play an important role in the development of
OA. It is reported that increased oxidative stress reduces chondrocyte
survival. N-acetylcysteine (NAC) is a thiol, a mucolytic agent, a precursor
of L-cysteine and reduced gluthathione, and scavenger of ROS. Chon-
drocytes are very sensitive to ROS, but can survive in the presence of
L-cysteine. The objective of this study is to examine the effect of anti-
apoptotic effect for chondrocyte by NAC.
Methods: The isolated chondrocytes of male japanease white rabbit were
cultured and the culture medium was replaced with presence or absence
of NAC. Sodium nitroprusside dehydrate (SNP) which is generates nitric
oxide (NO) was added to the culture medium for induction of apoptosis,
and the cells were cultured for 12hours. For DNA visualization, chondro-
cytes were stained with 2% Hoechst 33342. The cells were observed
under a ﬂuorescence microscope. Chondrocyte apoptosis was detected
by staining with TdT-mediated dUTP nick end labeling (TUNEL). Amount
of intercellular ROS was also evaluated. To ascertain wether glutathione is
involved, inhibition assay was performed by using glutathione synthetase
inhibitor, buthionine sulfoximine (BSO).
Results: In the NAC-untreated group with SNP, a generous amount
of chodrocytes exhibited typical characteristics of apoptosis with highly
fragmented, condensed or divided nuclei. In contrast, fewer apoptotic
cells observed in the NAC-treated culture. The positive rate of apoptotic
cell with SNP addition reduced signiﬁcantly by NAC treatment. Amount
of intercellular ROS was elevated transiently by SNP treatment, but
decreased signiﬁcantly by NAC. By the treatment of BSO the effect of
NAC was disappeared in all assays.
Conclusions: Those studies showed that ROS is involved in NO toxity.
NAC appeared to have remarkable protecting effect in chondrocytes
subjected to NO via glutathione synthesis. NAC has been used for
treatment of acetaminophen toxicity in clinical practice, and its safeness
has already conﬁrmed. In this study, These ﬁnding supports the possibility
that NAC could prevent the progression of OA through the suppression
of apoptosis.
180 CD90 AND CD166 REPRESENT PREDICTIVE MARKERS OF
EARLY CHONDROCYTES DEDIFFERENTIATION
S. Giovannini, J. Diaz-Romero, P. Mainil-Varlet, D. Nesic. Institute of
Pathology, Bern, SWITZERLAND
Purpose: Treatments of cartilage defect with tissue-engineering tech-
niques rely on the chondrogenic capacities of isolated and culture-
expanded cells. During expansion in monolayer, human articular chon-
drocytes (HAC) lose their chondrogenic potential and become depen-
dent on differentiation factors for neochodrogenesis. In this study, the
interconnection between dedifferentiation process, cell proliferation and
intrinsic/chondrogenic factors-dependent redifferentiation capacities was
established. Moreover, changes in the surface marker expression during
the early expansion phase was correlated with the intrinsic chondrogenic
capacites.
Methods: Hyaline cartilage samples were collected post-mortem from
human knee joints. After isolation, HAC were expanded in DMEM-F12
medium containing 10% FBS. Redifferentiation potential of HAC was
assessed in micromass pellets culture incubated for 3 weeks in high
glucose DMEM serum free media without (−T−D) or with (+T+D) TGF-
b1 (10 ng/ml) and dexamethasone (10−7 M). Proteoglycan synthesis was
evaluated via Safranin-O staining and collagen type II production via
immunohistochemistry. Cellularity and the glycosaminoglycans content of
the pellets were quantiﬁed using CyQuant kit and dimethylmethylene blue
dye binding assay respectively. Surface marker expression was monitored
during early expansion phase in monolayer using ﬂow cytometry.
Results: The requirement for chondrogenic factors was analyzed in
pellets produced by HAC expanded for 10 days (primary) and for 5 weeks
(passaged) HAC. Pellets from primary HAC cultured without the addition
of chondrogenic factors produced neocartilage tissue with extracellular
matrix rich in proteoglycans and collagen type II. In contrast, in pellets
from passaged HAC, the presence of both factors proved necessary for
neochondrogenesis. Thus, −T−D condition was identiﬁed as optimal to
assess HAC intrinsic chondrogenic potential. To identify when during
expansion HAC lose their intrinsic chondrogenic potential, cells were
expanded from 1 to 6 weeks in monolayer, and pellets were prepared.
Cell expansion corresponding to less than 3.2±0.4 cumulative population
doublings (PD) resulted in the formation of neocartilage tissue in −T−D
condition. In contrast, cells that underwent more than 3.2±0.4 cumulative
PD produced only ﬁbrous-like tissue indicating complete loss of intrinsic
chondrogenic potential. Chondrogenesis could be restored by the addition
of chondrogenic factors (+T+D). The GAG/DNA analysis indicated that
HAC expanded for 1 week produced higher amounts of GAGs in −T−D
compared to +T+D condition, suggesting inhibitory effect of chondrogenic
stimuli in the early expansion phase. However, already after 2 weeks
of expansion, the addition of chondrogenic stimuli had beneﬁcial effect.
To investigate whether changes in surface marker expression could be
related to the early dedifferentation process, several surface markers were
analyzed. A marked upregulation of CD90 and CD166 was observed after
10 days expansion in monolayer culture.
Conclusions: Loss of HAC intrinsic chondrogenic capacities in vitro
appears to be a continuous process which correlates with the prolifer-
ation rate of HAC, identifying 3.2±0.4 PD as a critical number of cell
divisions. The progressive loss of intrinsic redifferentiation potential can
be partly reversed by the presence of chondrogenic factors TGF-b1 and
dexamethasone as early as 14 days expansion. Upregulation of CD90
and CD166 after 10 days of expansion represents predictive marker of
early HAC dedifferentiation before complete loss of intrinsic chondrogenic
potential occurs.
181 SALMON CALCITONIN INCREASE PROTEOGLYCAN
FORMATION FORMATION IN HUMAN OA ARTICULAR
CARTILAGE
B-C. Sondergaard, S.H. Madsen, C. Christiansen, M.A. Karsdal. Nordic
Bioscience, Herlev, DENMARK
Purpose: Calcitonin has previously been demonstrated to have chon-
droprotective effects on articular cartilage under in vivo experimental
conditions. It is debated whether this effect is exclusively due to effect
on subchondral bone remodelling or in part due to direct effects on
the articular cartilage. We investigated possible direct anabolic effects
of calcitonin in human OA articular cartilage with focus on cartilage
formation of proteoglycans and collagen type II.
Methods: Human OA cartilage was obtained from knee arthroplasty
operations, which was dissected into 12−14mg explants and cultured
in six replicates with refreshment of medium every second or third day
in the presence or absence of salmon calcitonin [0.01pM-100 nM] in
DMEM:F12 supplemented with 2% Ultrose G. As positive control other
cartilage explants were stimulated with 100 ng/mL IGF and as negative
control for cell-mediated effects metabolic inactivated cartilage explants
were used. Direct effects of calcitonin on articular cartilage was evaluated
using (1) following proteoglycan synthesis by radioactive labeled 35SO4
[5mCi] after 18 days of culture and extracting the proteoglycans by 4M
GuHCl treatment, (2) investigations of metabolic activity using the cell
viability assay AlamarBlue, (3) collagen type II formation measured as
neoepitopes of propeptides of collagen type II was quantiﬁed by the PIINP
ELISA.
Results: Calcitonin signiﬁcantly (P< 0.01) and concentration-dependently
[0.01 pM-100 nM]. Induced proteoglycan synthesis measured by radioac-
tive sulphate incorporation with a 40% maximal induction at 10 nM, corre-
sponding to the levels of the positive control 100 ng/ml IGF. In alignment,
calcitonin treatment concentration-dependently [0.01 pM-100 nM] resulted
in signiﬁcant (P< 0.01) 35% increased levels of collagen type II synthesis.
Conclusions: Calcitonin treatment increased proteoglycan and collagen
synthesis of human OA cartilage. Calcitonin may provide beneﬁt to the
management of joint diseases via the direct effects on chondrocytes in
addition to the well-established osteoclast mediated effects on subchon-
dral bone.
